Human
papillomavirus
(
HPV
)
infection
causally
associated
benign
malignant
diseases
upper
airway
,
including
respiratory
papillomatosis
oropharyngeal
cancer
.

Low-risk
HPV
types
6
11
predominant
cause
papillomatosis
,
whereas
HPV16
definitively
satisfies
molecular
epidemiological
causal
criteria
carcinogenic
high-risk
type
upper
airway
.

HPV16
E6/E7
mRNA
expression
integration
observed
predominantly
among
oropharyngeal
cancers
,
experimental
models
shown
E6/E7
expression
necessary
initiation
maintenance
malignant
phenotype
cancers
.

From
epidemiological
perspective
,
strong
consistent
association
markers
HPV16
exposure
oropharyngeal
cancer
demonstrated
numerous
case-control
studies
.

HPV-positive
oropharyngeal
cancers
also
shown
distinct
HPV-negative
head
neck
squamous
cell
cancers
regard
risk-factor
profiles
,
molecular
genetic
alterations
,
population-level
incidence
trends
time
,
prognosis
.

Tumor
HPV
status
(
determined
certain
HPV16
situ
hybridization
assays
certain
p16
immunohistochemistry
assays
)
strongest
determinant
survival
patients
local-regionally
advanced
oropharyngeal
cancer
:
patients
HPV-positive
cancer
least
50
%
improvement
overall
survival
5
years
,
equivalent
approximate
30
%
difference
absolute
survival
.

Thus
,
HPV
status
determination
part
routine
diagnostic
evaluation
prognostication
.

Preliminary
evidence
indicates
small
proportion
head
neck
cancers
may
caused
additional
HPV
types
(
e.g.
,
18
,
31
,
33
,
35
)
HPV-caused
cancers
may
rarely
arise
non-oropharyngeal
sites
(
e.g.
,
oral
cavity
,
nasopharynx
,
larynx
)
.

Whether
HPV
vaccination
potential
prevent
oral
HPV
infections
lead
cancer
papillomatosis
upper
airway
currently
unknown
,
potential
secondary
prevention
HPV
detection
.

This
article
forms
part
special
supplement
entitled
``
Comprehensive
Control
HPV
Infections
Related
Diseases
''
Vaccine
Volume
30
,
Supplement
5
,
2012
.

